Islet autoantibody types mark differential clinical characteristics at diagnosis of pediatric type 1 diabetes.
autoantibody
diagnosis
heterogeneity
pediatric
type 1 diabetes
Journal
Pediatric diabetes
ISSN: 1399-5448
Titre abrégé: Pediatr Diabetes
Pays: Denmark
ID NLM: 100939345
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
20
04
2021
received:
10
02
2021
accepted:
18
05
2021
pubmed:
22
5
2021
medline:
2
2
2022
entrez:
21
5
2021
Statut:
ppublish
Résumé
We aimed to study whether islet autoantibody type marks differential characteristics at the time of type 1 diabetes (T1D) diagnosis. We studied 711 children with newly diagnosed autoimmune T1D. We compared demographic (sex, age, race/ethnicity), clinical (pubertal development, BMI percentile, diabetic ketoacidosis [DKA]) and laboratory (glucose, hemoglobin A1c [HbA1c], C-peptide, tissue transglutaminase antibodies [tTGA], thyroglobulin antibodies, and thyroid peroxidase antibodies [TPOA]) characteristics by presence/absence of autoantibodies to insulin (IAA), GAD65 (GADA), or IA-2/ICA512 (IA-2A). Islet autoantibody titers were evaluated among the children positive for the relevant autoantibody type. We used multivariable analysis to adjust for potential confounders. IAA+ was statistically associated with younger age (p < 0.0001) and lower HbA1c (p = 0.049) while Tanner stage, GADA status and number of positive islet autoantibodies were not significant in the multivariable model. GADA+ was associated with female sex (OR = 4.0, p = 0.002) and negatively with elevated tTGA titers (>50 U/mL) (OR = 0.21, p = 0.026) but not with age, IAA status, IA-2A status, islet autoantibody number, or thyroid autoimmunity. None of the associations with IA-2A positivity was statistically significant in the multivariable analysis. In multivariable models, IAA titer was significantly associated with younger age (p = 0.006), DKA (p = 0.017) and higher tTGA levels (p = 0.002); GADA titer with female sex (p = 0.028), racial minority (p = 0.046) and TPOA positivity (p = 0.021); and IA-2A titer with older age (p = 0.001) and not being African American (p = 0.024). Islet autoantibody type is associated with differential characteristics at diagnosis of pediatric T1D. Longitudinal and mechanistic studies are needed to evaluate T1D endotypes by autoantibody type.
Sections du résumé
BACKGROUND
We aimed to study whether islet autoantibody type marks differential characteristics at the time of type 1 diabetes (T1D) diagnosis.
METHODS
We studied 711 children with newly diagnosed autoimmune T1D. We compared demographic (sex, age, race/ethnicity), clinical (pubertal development, BMI percentile, diabetic ketoacidosis [DKA]) and laboratory (glucose, hemoglobin A1c [HbA1c], C-peptide, tissue transglutaminase antibodies [tTGA], thyroglobulin antibodies, and thyroid peroxidase antibodies [TPOA]) characteristics by presence/absence of autoantibodies to insulin (IAA), GAD65 (GADA), or IA-2/ICA512 (IA-2A). Islet autoantibody titers were evaluated among the children positive for the relevant autoantibody type. We used multivariable analysis to adjust for potential confounders.
RESULTS
IAA+ was statistically associated with younger age (p < 0.0001) and lower HbA1c (p = 0.049) while Tanner stage, GADA status and number of positive islet autoantibodies were not significant in the multivariable model. GADA+ was associated with female sex (OR = 4.0, p = 0.002) and negatively with elevated tTGA titers (>50 U/mL) (OR = 0.21, p = 0.026) but not with age, IAA status, IA-2A status, islet autoantibody number, or thyroid autoimmunity. None of the associations with IA-2A positivity was statistically significant in the multivariable analysis. In multivariable models, IAA titer was significantly associated with younger age (p = 0.006), DKA (p = 0.017) and higher tTGA levels (p = 0.002); GADA titer with female sex (p = 0.028), racial minority (p = 0.046) and TPOA positivity (p = 0.021); and IA-2A titer with older age (p = 0.001) and not being African American (p = 0.024).
CONCLUSIONS
Islet autoantibody type is associated with differential characteristics at diagnosis of pediatric T1D. Longitudinal and mechanistic studies are needed to evaluate T1D endotypes by autoantibody type.
Substances chimiques
Autoantibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
882-888Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Battaglia M, Ahmed S, Anderson MS, et al. Introducing the Endotype concept to address the challenge of disease heterogeneity in type 1 diabetes. Diabetes Care. 2020;43(1):5-12. https://doi.org/10.2337/dc19-0880.
Gorus FK, Balti EV, Messaaoui A, et al. Twenty-year progression rate to clinical onset according to autoantibody profile, age, and. Diabetes Care. 2017;40(8):1065-1072. https://doi.org/10.2337/dc16-2228.
Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473-2479. https://doi.org/10.1001/jama.2013.6285.
Balke EM, Balti EV, Van der Auwera B, et al. Accelerated progression to type 1 diabetes in the presence of. Diabetes Care. 2018;41(5):1076-1083. https://doi.org/10.2337/dc17-2462.
Krischer JP, Lynch KF, Schatz DA, et al. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia. 2015;58(5):980-987. https://doi.org/10.1007/s00125-015-3514-y.
Krischer JP, Lynch KF, Lernmark Å, et al. Genetic and environmental interactions modify the risk of diabetes-related autoimmunity by 6 years of age: the TEDDY study. Diabetes Care. 2017;40(9):1194-1202. https://doi.org/10.2337/dc17-0238.
Bingley PJ, Boulware DC, Krischer JP, Group TDTS. The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes. Diabetologia. 2016;59(3):542-549. https://doi.org/10.1007/s00125-015-3830-2.
Vehik K, Bonifacio E, Lernmark Å, et al. Hierarchical order of distinct autoantibody spreading and progression to type 1 diabetes in the TEDDY study. Diabetes Care. 2020;43(9):2066-2073. https://doi.org/10.2337/dc19-2547.
Redondo MJ, Rodriguez LM, Escalante M, Smith EO, Balasubramanyam A, Haymond MW. Types of pediatric diabetes mellitus defined by anti-islet autoimmunity and random C-peptide at diagnosis. Pediatr Diabetes. 2013;14(5):333-340. https://doi.org/10.1111/pedi.12022.
Redondo MJ, Rodriguez LM, Escalante M, O'Brian Smith E, Balasubramanyam A, Haymond MW. Beta cell function and BMI in ethnically diverse children with newly diagnosed autoimmune type 1 diabetes. Pediatr Diabetes. 2012;13(7):564-571. https://doi.org/10.1111/j.1399-5448.2012.00875.x.
Sulkanen S, Halttunen T, Laurila K, et al. Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. Gastroenterology. 1998;115(6):1322-1328. https://doi.org/10.1016/s0016-5085(98)70008-3.
Leete P, Oram RA, McDonald TJ, et al. Studies of insulin and proinsulin in pancreas and serum support the existence of aetiopathological endotypes of type 1 diabetes associated with age at diagnosis. Diabetologia. 2020;63(6):1258-1267. https://doi.org/10.1007/s00125-020-05115-6.
Leete P, Willcox A, Krogvold L, et al. Differential Insulitic profiles determine the extent of β-cell destruction and the age at onset of type 1 diabetes. Diabetes. 05 2016;65(5):1362-1369. doi:https://doi.org/10.2337/db15-1615
Wessels M, Velthuis A, van Lochem E, et al. Raising the cut-off level of anti-tissue transglutaminase antibodies to detect celiac disease reduces the number of small bowel biopsies in children with type 1 diabetes: a retrospective study. J Pediatr. 2020;223:87-92. https://doi.org/10.1016/j.jpeds.2020.02.086.
Chung WK, Erion K, Florez JC, et al. Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2020;43(7):1617-1635. https://doi.org/10.2337/dci20-0022.
Dabelea D, Pihoker C, Talton JW, et al. Etiological approach to characterization of diabetes type: the SEARCH for diabetes in youth study. Diabetes Care. 2011;34(7):1628-1633. https://doi.org/10.2337/dc10-2324.
Ilonen J, Lempainen J, Hammais A, et al. Primary islet autoantibody at initial seroconversion and autoantibodies at diagnosis of type 1 diabetes as markers of disease heterogeneity. Pediatr Diabetes. 2018;19(2):284-292. https://doi.org/10.1111/pedi.12545.
Yu L, Robles DT, Abiru N, et al. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci U S A. 2000;97(4):1701-1706. https://doi.org/10.1073/pnas.040556697.
Eisenbarth GS, Gianani R, Yu L, et al. Dual-parameter model for prediction of type I diabetes mellitus. Proc Assoc Am Physicians. 1998;110(2):126-135.
Ilonen J, Hammais A, Laine AP, et al. Patterns of β-cell autoantibody appearance and genetic associations during the first years of life. Diabetes. 2013;62(10):3636-3640. https://doi.org/10.2337/db13-0300.
Leete P, Mallone R, Richardson SJ, Sosenko JM, Redondo MJ, Evans-Molina C. The effect of age on the progression and severity of type 1 diabetes: potential effects on disease mechanisms. Curr Diab Rep. 09 2018;18(11):115. doi:https://doi.org/10.1007/s11892-018-1083-4
Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-1974. https://doi.org/10.2337/dc15-1419.
Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. N Engl J Med. 2017;376(15):1419-1429. https://doi.org/10.1056/NEJMoa1610187.
Cohn A, Sofia AM, Kupfer SS. Type 1 diabetes and celiac disease: clinical overlap and new insights into disease pathogenesis. Curr Diab Rep. 2014;14(8):517. https://doi.org/10.1007/s11892-014-0517-x.
Arvan P, Pietropaolo M, Ostrov D, Rhodes CJ. Islet autoantigens: structure, function, localization, and regulation. Cold Spring Harb Perspect Med. 2012;2(8):1-19. https://doi.org/10.1101/cshperspect.a007658.
Kahles H, Fain PR, Baker P, Eisenbarth G, Badenhoop K. Genetics of autoimmune thyroiditis in type 1 diabetes reveals a novel association with DPB1*0201: data from the type 1 diabetes genetics consortium. Diabetes Care. 2015;38(Suppl 2):S21-S28. https://doi.org/10.2337/dcs15-2005.
Mortensen HB, Swift PG, Holl RW, et al. Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis. Pediatr Diabetes. 2010;11(4):218-226. https://doi.org/10.1111/j.1399-5448.2009.00566.x.
Sorensen JS, Vaziri-Sani F, Maziarz M, et al. Islet autoantibodies and residual beta cell function in type 1 diabetes children followed for 3-6 years. Diabetes Res Clin Pract. 2012;96(2):204-210. https://doi.org/10.1016/j.diabres.2011.12.013.
Juusola M, Parkkola A, Härkönen T, et al. Positivity for zinc transporter 8 autoantibodies at diagnosis is subsequently associated with reduced β-cell function and higher exogenous insulin requirement in children and adolescents with type 1 diabetes. Diabetes Care. 2016;39(1):118-121. https://doi.org/10.2337/dc15-1027.